GoldenGolden
Advanced Search
COMPASS Pathways

COMPASS Pathways

COMPASS Pathways is a life sciences company founded in 2016, based in London, UK, that develops clinical research programs and treatments for depression and works to accelerate patient access to evidence-based innovations in mental health.

COMPASS Pathways received Breakthrough Therapy designation in Autumn 2018 from the US Food and Drug Administration (FDA) for its psilocybin therapy to treat depression. COMPASS Pathways will run a large-scale psilocybin therapy clinical trial for treatment-resistant depression in Europe and North America in 2018-2019.

Psilocybin therapy uses psilocybin, the psychoactive ingredient in the psilocybin mushrooms, also known as “magic mushrooms”, and is given along with psychological support. In the UK and the US, Psilocybin therapy how shown promise in terms of efficacy and safety for depression treatment in academic studies.

COMPASS Pathways is making psilocybin available free of charge through the Medicines Chest programme to the European College of Neuropsychopharmacology (ECNP).

Timeline

April 27, 2020
COMPASS Pathways raises a $80,000,000 series B round from ATAI Life Sciences, Able Partners NYC, Camden Partners, Founders Fund, Perceptive Advisors and Skyviews Life Sciences.
October 3, 2018
COMPASS Pathways raises a $32,500,000 series A round.
August 17, 2017
COMPASS Pathways raises a $3,870,000 seed round.

Funding rounds

People

Name
Role
LinkedIn

Ekaterina Malievskaia

Co-Founder, Chief Medical Officer

George Goldsmith

Co-Founder, Chairman

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Yeji Jesse Lee
June 1, 2021
Business Insider
The outcome could determine who gets to profit from using psychedelics as treatments for conditions like depression and PTSD.
FinancialNewsMedia.com
May 25, 2021
www.prnewswire.com:443
/PRNewswire/ -- Recently, the use of psychedelics is evolving for the treatment of a variety of mental illnesses, including anxiety, depression, post-traumatic...
Yeji Jesse Lee
April 22, 2021
Business Insider
Atai wants to use ibogaine, ketamine, and other psychedelic compounds as treatments for mental-health conditions.
Yeji Jesse Lee
April 14, 2021
Business Insider
For the first time, researchers pitted psilocybin, the active compound in magic mushrooms, against a leading antidepressant.
BioSpace
April 13, 2021
BioSpace
Quercis Pharma AG, a private, clinical stage biopharmaceutical company leveraging its novel antithrombotic platform, announces the appointment of several new executives to the Company's leadership team.
Melanie Senior
April 1, 2021
Nature Biotechnology
Private biotech firms are awash with funding, raising record-breaking sums in 2020. Melanie Senior reports.
Sian Bradley
March 1, 2021
Sifted
European companies like Compass Pathways, Berkley Psytech and Atai Life Sciences are leading the race to dominate the new psychedelics market.
Peptilogics
December 21, 2020
www.prnewswire.com:443
/PRNewswire/ -- Peptilogics announced today the closing of a $35.4 million Series B financing. The financing was led by Presight Capital, with participation...
Dr. Catherine Schuster-Bruce
December 17, 2020
Business Insider
There's a new UK venture fund, Neo Kuma, dedicated to psychedelics. Cofounder Clara Burtenshaw sets out her strategy for the emerging and risky field.
Kevin O'Leary
November 17, 2020
Business Insider
With Oregon as the first-ever state to legalize psychedelics on election day, the Shark Tank investor shares three things to look out for.
Michael Stothard
November 16, 2020
Sifted
Christian Angermayer has been one of the investors most resonsible for the global psychedelic renaissance with Compass Pathways and Atai Life Sciences.
Jonah Engel Bromwich
February 28, 2020
www.nytimes.com
Venture capital arrives for psychedelics.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.